Chronic kidney disease (CKD) is a silent epidemic. In this high-stakes space, biotechnology companies focused on reversing or ...

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Research reveals why EGFR-targeted cancer therapies often face resistance, leading to ongoing studies on combination treatments.

Oncology, a team of expert scientists specializing in immuno-oncology extensively outlined the complexities involved in the ...

MUSC Hollings Cancer Center researchers have discovered a hidden feedback loop that helps leukemia cells survive and have developed a new immunotherapy that can break that loop. The loop is between a ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.